Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Accounts Payables (2021 - 2025)

Aligos Therapeutics' Accounts Payables history spans 5 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 54.88% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, up 54.88%, while the annual FY2025 figure was $4.0 million, 54.88% up from the prior year.
  • Accounts Payables reached $4.0 million in Q4 2025 per ALGS's latest filing, down from $4.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.8 million in Q2 2024 to a low of $1.6 million in Q2 2021.
  • Average Accounts Payables over 5 years is $3.4 million, with a median of $2.9 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: tumbled 46.87% in 2023, then soared 110.4% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $3.0 million in 2021, then surged by 57.11% to $4.7 million in 2022, then crashed by 46.87% to $2.5 million in 2023, then increased by 2.15% to $2.6 million in 2024, then surged by 54.88% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Accounts Payables are $4.0 million (Q4 2025), $4.7 million (Q3 2025), and $3.9 million (Q2 2025).